{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:47:05Z","timestamp":1793134025540,"version":"4.5.0"},"reference-count":55,"publisher":"Pleiades Publishing Ltd","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biochemistry Moscow"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1134\/s0006297925603284","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:06:50Z","timestamp":1773414410000},"page":"274-288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Proteasome Inhibition as a Cancer Type-Specific Off-Target Effect of Everolimus in Cancer Cells"],"prefix":"10.1134","volume":"91","author":[{"given":"Anna S.","family":"Vorobeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizaveta M.","family":"Kazakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla A.","family":"Garibova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria D.","family":"Emekeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomiris T.","family":"Kusainova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan I.","family":"Fedorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey A.","family":"Shelepchikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey V.","family":"Tretyakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton O.","family":"Chugunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail V.","family":"Gorshkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina A.","family":"Tarasova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"137","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"3004_CR1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cmet.2014.01.001","volume":"19","author":"J. Li","year":"2014","unstructured":"Li, J., Kim, S. G., and Blenis, J. (2014) Rapamycin: one drug, many effects, Cell Metab., 19, 373-379, \nhttps:\/\/doi.org\/10.1016\/j.cmet.2014.01.001.","journal-title":"Cell Metab."},{"key":"3004_CR2","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1093\/neuonc\/nov152","volume":"17","author":"J. K. MacKeigan","year":"2015","unstructured":"MacKeigan, J. K., and Krueger, D. A. (2015) Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex, Neuro Oncol., 17, 1550-1559, \nhttps:\/\/doi.org\/10.1093\/neuonc\/nov152.","journal-title":"Neuro Oncol."},{"key":"3004_CR3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/aps.2015.68","volume":"36","author":"L. Meng","year":"2015","unstructured":"Meng, L., and Zheng, X. S. (2015) Toward rapamycin analog (rapalog)-based precision cancer therapy, Acta Pharmacol. Sin., 36, 1163-1169, \nhttps:\/\/doi.org\/10.1038\/aps.2015.68.","journal-title":"Acta Pharmacol. Sin."},{"key":"3004_CR4","doi-asserted-by":"publisher","first-page":"S495","DOI":"10.1016\/j.transproceed.2004.01.015","volume":"36","author":"R. N. Formica","year":"2004","unstructured":"Formica, R. N., Lorber, K. M., Friedman, A. L., Bia, M. J., Lakkis, F., Smith, J. D., and Lorber, M. I. (2004) The evolving experience using everolimus in clinical transplantation, Transplant. Proceed., 36, S495-S499, \nhttps:\/\/doi.org\/10.1016\/j.transproceed.2004.01.015.","journal-title":"Transplant. Proceed."},{"key":"3004_CR5","unstructured":"Everolimus: Uses, Interactions, Mechanism of Action|DrugBank Online. URL: https:\/\/go.drugbank.com\/drugs\/DB01590. Accessed 05.11.2025."},{"key":"3004_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1717-8","volume":"15","author":"V. Simone","year":"2015","unstructured":"Simone, V., Ciavarella, S., Brunetti, O., Savonarola, A., Cives, M., Tucci, M., Opinto, G., Maiorano, E., and Silvestris, F. (2015) Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells, BMC Cancer, 15, 692, \nhttps:\/\/doi.org\/10.1186\/s12885-015-1717-8.","journal-title":"BMC Cancer"},{"key":"3004_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17111827","volume":"17","author":"L. Mercatali","year":"2016","unstructured":"Mercatali, L., Spadazzi, C., Miserocchi, G., Liverani, C., De Vita, A., Bongiovanni, A., Recine, F., Amadori, D., and Ibrahim, T. (2016) The effect of everolimus in an in vitro model of triple negative breast cancer and osteoclasts, Int. J. Mol. Sci., 17, 1827, \nhttps:\/\/doi.org\/10.3390\/ijms17111827.","journal-title":"Int. J. Mol. Sci."},{"key":"3004_CR8","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1021\/acsptsci.3c00316","volume":"7","author":"A. A. Lobas","year":"2024","unstructured":"Lobas, A. A., Saei, A. A., Lyu, H., Zubarev, R. A., and Gorshkov, M. V. (2024) Chemical proteomics reveals that the anticancer drug everolimus affects the ubiquitin-proteasome system, ACS Pharmacol. Transl. Sci., 7, 787-796, \nhttps:\/\/doi.org\/10.1021\/acsptsci.3c00316.","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"3004_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0092-8674(94)90396-4","volume":"79","author":"A. Ciechanover","year":"1994","unstructured":"Ciechanover, A. (1994) The ubiquitin-proteasome proteolytic pathway, Cell, 79, 13-21, \nhttps:\/\/doi.org\/10.1016\/0092-8674(94)90396-4.","journal-title":"Cell"},{"key":"3004_CR10","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S0955-0674(97)80079-8","volume":"9","author":"A. Hershko","year":"1997","unstructured":"Hershko, A. (1997) Roles of ubiquitin-mediated proteolysis in cell cycle control, Curr. Opin. Cell Biol., 9, 788-799, \nhttps:\/\/doi.org\/10.1016\/S0955-0674(97)80079-8.","journal-title":"Curr. Opin. Cell Biol."},{"key":"3004_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/sj.cdd.4400505","volume":"6","author":"R. Z. Orlowski","year":"1999","unstructured":"Orlowski, R. Z., (1999) The role of the ubiquitin-proteasome pathway in apoptosis, Cell Death Differ., 6, 303-313, \nhttps:\/\/doi.org\/10.1038\/sj.cdd.4400505.","journal-title":"Cell Death Differ."},{"key":"3004_CR12","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","volume":"23","author":"S. V. Rajkumar","year":"2005","unstructured":"Rajkumar, S. V., Richardson, P. G., Hideshima, T., and Anderson, K. C. (2005) Proteasome inhibition as a novel therapeutic target in human cancer, J.\u00a0Clin. Oncol., 23, 630-639, \nhttps:\/\/doi.org\/10.1200\/JCO.2005.11.030.","journal-title":"J.\u00a0Clin. Oncol."},{"key":"3004_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2174\/1568009614666140804154511","volume":"14","author":"Q. Dou","year":"2014","unstructured":"Dou, Q., and Zonder, J. (2014) Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system, Curr. Cancer Drug Targets, 14, 517-536, \nhttps:\/\/doi.org\/10.2174\/1568009614666140804154511.","journal-title":"Curr. Cancer Drug Targets"},{"key":"3004_CR14","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.ctrv.2005.10.001","volume":"31","author":"G. Jackson","year":"2005","unstructured":"Jackson, G., Einsele, H., Moreau, P., and Miguel, J.\u00a0S. (2005) Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies, Cancer Treat. Rev., 31, 591-602, \nhttps:\/\/doi.org\/10.1016\/j.ctrv.2005.10.001.","journal-title":"Cancer Treat. Rev."},{"key":"3004_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/jim-2018-000780","volume":"67","author":"J. Li","year":"2019","unstructured":"Li, J., Liu, Z., Li, Y., Jing, Q., Wang, H., Liu, H., Chen, J., Feng, J., Shao, Q., and Fu, R. (2019) Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT\/mTOR pathway, J.\u00a0Invest. Med., 67, 39-47, \nhttps:\/\/doi.org\/10.1136\/jim-2018-000780.","journal-title":"J.\u00a0Invest. Med."},{"key":"3004_CR16","unstructured":"Proteasome subunit beta type-5|DrugBank Online. URL: https:\/\/go.drugbank.com\/bio_entities\/BE0002348. Accessed 28.11.2025."},{"key":"3004_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep11176","volume":"5","author":"A. Chernobrovkin","year":"2015","unstructured":"Chernobrovkin, A., Marin-Vicente, C., Visa, N., and Zubarev, R.\u00a0A. (2015) Functional Identification of Target by Expression Proteomics (FITExP) reveals protein targets and highlights mechanisms of action of small molecule drugs, Sci Rep., 5, 11176, \nhttps:\/\/doi.org\/10.1038\/srep11176.","journal-title":"Sci Rep."},{"key":"3004_CR18","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/nature03192","volume":"432","author":"C. M. Dobson","year":"2004","unstructured":"Dobson, C. M. (2004) Chemical space and biology, Nature, 432, 824-828, \nhttps:\/\/doi.org\/10.1038\/nature03192.","journal-title":"Nature"},{"key":"3004_CR19","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1134\/S0006297924080017","volume":"89","author":"I. I. Fedorov","year":"2024","unstructured":"Fedorov, I. I., Protasov, S. A., Tarasova, I. A., and Gorshkov, M.\u00a0V. (2024) Ultrafast proteomics, Biochemistry (Moscow), 89, 1349-1361, \nhttps:\/\/doi.org\/10.1134\/S0006297924080017.","journal-title":"Biochemistry (Moscow)"},{"key":"3004_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.202200013","volume":"23","author":"C. B. Messner","year":"2023","unstructured":"Messner, C. B., Demichev, V., Wang, Z., Hartl, J., Kustatscher, G., M\u00fclleder, M., and Ralser, M. (2023) Mass spectrometry-based high-throughput proteomics and its role in biomedical studies and systems biology, Proteomics, 23, 2200013, \nhttps:\/\/doi.org\/10.1002\/pmic.202200013.","journal-title":"Proteomics"},{"key":"3004_CR21","doi-asserted-by":"publisher","first-page":"13068","DOI":"10.1021\/acs.analchem.2c02255","volume":"94","author":"M. V. Ivanov","year":"2022","unstructured":"Ivanov, M. V., Bubis, J. A., Gorshkov, M. V., Tarasova, I.\u00a0A., Levitsky, L.\u00a0I. (2022) DirectMS1Quant: ultrafast quantitative proteomics with MS\/MS-free mass spectrometry, Anal. Chem., 94, 13068-13075, \nhttps:\/\/doi.org\/10.1021\/acs.analchem.2c02255.","journal-title":"Anal. Chem."},{"key":"3004_CR22","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1021\/jasms.4c00134","volume":"35","author":"M. V. Ivanov","year":"2024","unstructured":"Ivanov, M. V., Kopeykina, A. S., and Gorshkov, M.\u00a0V. (2024) Reanalysis of DIA data demonstrates the capabilities of MS\/MS-free proteomics to reveal new biological insights in disease-related samples, J. Am. Soc. Mass Spectrom., 35, 1775-1785, \nhttps:\/\/doi.org\/10.1021\/jasms.4c00134.","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"3004_CR23","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1007\/s00216-024-05330-9","volume":"416","author":"I. I. Fedorov","year":"2024","unstructured":"Fedorov, I. I., Bubis, J. A., Kazakova, E. M., Lobas, A.\u00a0A., Ivanov, M.\u00a0V., Emekeeva, D.\u00a0D., Tarasova, I.\u00a0A., Nazarov, A.\u00a0A., and Gorshkov, M.\u00a0V. (2024) On the utility of ultrafast MS1-only proteomics in drug target discovery studies based on thermal proteome profiling method, Anal. Bioanal. Chem., 416, 4083-4089, \nhttps:\/\/doi.org\/10.1007\/s00216-024-05330-9.","journal-title":"Anal. Bioanal. Chem."},{"key":"3004_CR24","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1021\/acsptsci.4c00718","volume":"8","author":"E. A. Imaikina","year":"2025","unstructured":"Imaikina, E. A., Fedorov, I. I., Kazakova, E.\u00a0M., Garibova, L.\u00a0A., Ivanov, M.\u00a0V., Shutkov, I. A., Nazarov, A.\u00a0A., Gorshkov, M.\u00a0V., and Tarasova, I.\u00a0A. (2025) Study on the mechanism of action of the Pt(IV) complex with lonidamine ligands by ultrafast chemical proteomics, ACS Pharmacol. Transl. Sci., 8, 1106-1115, \nhttps:\/\/doi.org\/10.1021\/acsptsci.4c00718.","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"3004_CR25","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1134\/S000629792211013X","volume":"87","author":"E. M. Solovyeva","year":"2022","unstructured":"Solovyeva, E. M., Bubis, J.\u00a0A., Tarasova, I.\u00a0A., Lobas, A.\u00a0A., Ivanov, M.\u00a0V., Nazarov, A.\u00a0A., Shutkov, I.\u00a0A., and Gorshkov, M.\u00a0V. (2022) On the feasibility of using an ultra-fast DirectMS1 method of proteome-wide analysis for searching drug targets in chemical proteomics, Biochemistry (Moscow), 87, 1342-1353, \nhttps:\/\/doi.org\/10.1134\/S000629792211013X.","journal-title":"Biochemistry (Moscow)"},{"key":"3004_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F. Bray","year":"2024","unstructured":"Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., and Jemal, A. (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, Cancer J. Clinic., 74, 229-263, \nhttps:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"Cancer J. Clinic."},{"key":"3004_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1124\/mol.112.083873","volume":"84","author":"P. A. Osmulski","year":"2013","unstructured":"Osmulski, P. A., and Gaczynska, M. (2013) Rapamycin allosterically inhibits the proteasome, Mol. Pharmacol., 84, 104-113, \nhttps:\/\/doi.org\/10.1124\/mol.112.083873.","journal-title":"Mol. Pharmacol."},{"key":"3004_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.9045","volume":"2021","author":"D. A. Abdrakhimov","year":"2021","unstructured":"Abdrakhimov, D. A., Bubis, J.\u00a0A., Gorshkov, V., Kjeldsen, F., Gorshkov, M.\u00a0V., and Ivanov, M.\u00a0V. (2021) Biosaur: an open-source Python software for liquid chromatography-mass spectrometry peptide feature detection with ion mobility support, Rapid Comm. Mass Spectrom., 2021, e9045, \nhttps:\/\/doi.org\/10.1002\/rcm.9045.","journal-title":"Rapid Comm. Mass Spectrom."},{"key":"3004_CR29","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1021\/acs.jproteome.7b00365","volume":"16","author":"M. V. Ivanov","year":"2017","unstructured":"Ivanov, M. V., Tarasova, I. A., Levitsky, L. I., Solovyeva, E.\u00a0M., Pridatchenko, M.\u00a0L., Lobas, A.\u00a0A., Bubis, J.\u00a0A., and Gorshkov, M.\u00a0V. (2017) MS\/MS-Free protein identification in complex mixtures using multiple enzymes with complementary specificity, J.\u00a0Proteome Res., 16, 3989-3999, \nhttps:\/\/doi.org\/10.1021\/acs.jproteome.7b00365.","journal-title":"J.\u00a0Proteome Res."},{"key":"3004_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nmeth1019","volume":"4","author":"J. E. Elias","year":"2007","unstructured":"Elias, J. E., and Gygi, S. P. (2007) Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry, Nat. Methods, 4, 207-214, \nhttps:\/\/doi.org\/10.1038\/nmeth1019.","journal-title":"Nat. Methods"},{"key":"3004_CR31","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1074\/mcp.O117.067728","volume":"16","author":"B. Zhang","year":"2017","unstructured":"Zhang, B., Pirmoradian, M., Zubarev, R., and K\u00e4ll, L. (2017) Covariation of peptide abundances accurately reflects protein concentration differences, Mol. Cell. Proteomics, 16, 936-948, \nhttps:\/\/doi.org\/10.1074\/mcp.O117.067728.","journal-title":"Mol. Cell. Proteomics"},{"key":"3004_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.202200275","volume":"23","author":"E. M. Kazakova","year":"2023","unstructured":"Kazakova, E. M., Solovyeva, E.\u00a0M., Levitsky, L.\u00a0I., Bubis, J.\u00a0A., Emekeeva, D. D., Antonets, A.\u00a0A., Nazarov, A.\u00a0A., Gorshkov, M.\u00a0V., and Tarasova, I.\u00a0A. (2023) Proteomics-based scoring of cellular response to stimuli for improved characterization of signaling pathway activity, Proteomics, 23, 2200275, \nhttps:\/\/doi.org\/10.1002\/pmic.202200275.","journal-title":"Proteomics"},{"key":"3004_CR33","doi-asserted-by":"publisher","first-page":"W501","DOI":"10.1093\/nar\/gkx372","volume":"45","author":"W. Luo","year":"2017","unstructured":"Luo, W., Pant, G., Bhavnasi, Y. K., Blanchard, S. G., and Brouwer, C. (2017) Pathview Web: user friendly pathway visualization and data integration, Nucleic Acids Res., 45, W501-W508, \nhttps:\/\/doi.org\/10.1093\/nar\/gkx372.","journal-title":"Nucleic Acids Res."},{"key":"3004_CR34","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1093\/bioinformatics\/btt285","volume":"29","author":"W. Luo","year":"2013","unstructured":"Luo, W., and Brouwer, C. (2013) Pathview: an R\/Bioconductor package for pathway-based data integration and visualization, Bioinformatics, 29, 1830-1831, \nhttps:\/\/doi.org\/10.1093\/bioinformatics\/btt285.","journal-title":"Bioinformatics"},{"key":"3004_CR35","doi-asserted-by":"publisher","first-page":"D730","DOI":"10.1093\/nar\/gkae1113","volume":"53","author":"D. Szklarczyk","year":"2025","unstructured":"Szklarczyk, D., Nastou, K., Koutrouli, M., Kirsch, R., Mehryary, F., Hachilif, R., Hu, D., Peluso, M. E., Huang, Q., Fang, T., Doncheva, N. T., Pyysalo, S., Bork, P., Jensen, L. J., and Von Mering, C. (2025) The STRING database in 2025: protein networks with directionality of regulation, Nucleic Acids Res., 53, D730-D737, \nhttps:\/\/doi.org\/10.1093\/nar\/gkae1113.","journal-title":"Nucleic Acids Res."},{"key":"3004_CR36","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/bioinformatics\/btr671","volume":"30","author":"Y. Xiao","year":"2012","unstructured":"Xiao, Y., Hsiao, T., Suresh, U., Chen, H. H., Wu, X., Wolf, S. E., and Chen, Y. (2012) A novel significance score for gene selection and ranking, Bioinformatics, 30, 801-807, \nhttps:\/\/doi.org\/10.1093\/bioinformatics\/btr671.","journal-title":"Bioinformatics"},{"key":"3004_CR37","doi-asserted-by":"publisher","DOI":"10.1101\/2025.06.14.659707","author":"S. Passaro","year":"2025","unstructured":"Passaro, S., Corso, G., Wohlwend, J., Reveiz, M., Thaler, S., Somnath, V. R., Getz, N., Portnoi, T., Roy, J., Stark, H., Kwabi-Addo, D., Beaini, D., Jaakkola, T., and Barzilay, R. (2025) Boltz-2: towards accurate and efficient binding affinity prediction, bioRxiv, \nhttps:\/\/doi.org\/10.1101\/2025.06.14.659707.","journal-title":"bioRxiv"},{"key":"3004_CR38","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1126\/science.aaf8993","volume":"353","author":"J. Schrader","year":"2016","unstructured":"Schrader, J., Henneberg, F., Mata, R. A., Tittmann, K., Schneider, T. R., Stark, H., Bourenkov, G., and Chari, A. (2016) The inhibition mechanism of human 20 S proteasomes enables next-generation inhibitor design, Science, 353, 594-598, \nhttps:\/\/doi.org\/10.1126\/science.aaf8993.","journal-title":"Science"},{"key":"3004_CR39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2183\/pjab.85.12","volume":"85","author":"K. Tanaka","year":"2009","unstructured":"Tanaka, K. (2009) The proteasome: overview of structure and functions, Proc. Jpn. Acad. Ser.\u00a0B, 85, 12-36, \nhttps:\/\/doi.org\/10.2183\/pjab.85.12.","journal-title":"Proc. Jpn. Acad. Ser.\u00a0B"},{"key":"3004_CR40","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1111\/j.1349-7006.2012.02359.x","volume":"103","author":"M. Yunokawa","year":"2012","unstructured":"Yunokawa, M., Koizumi, F., Kitamura, Y., Katanasaka, Y., Okamoto, N., Kodaira, M., Yonemori, K., Shimizu, C., Ando, M., Masutomi, K., Yoshida, T., Fujiwara, Y., and Tamura, K. (2012) Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells, Cancer Sci., 103, 1665-1671, \nhttps:\/\/doi.org\/10.1111\/j.1349-7006.2012.02359.x.","journal-title":"Cancer Sci."},{"key":"3004_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3230-8","volume":"17","author":"G. Ariaans","year":"2017","unstructured":"Ariaans, G., Jalving, M., De Vries, E. G. E., and De Jong, S. (2017) Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells, BMC Cancer, 17, 232, \nhttps:\/\/doi.org\/10.1186\/s12885-017-3230-8.","journal-title":"BMC Cancer"},{"key":"3004_CR42","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.tjog.2020.09.008","volume":"59","author":"T. Xu","year":"2020","unstructured":"Xu, T., Liu, P., Li, Q., Shi, C., and Wang, X. (2020) Inhibitory effects of everolimus in combination with paclitaxel on adriamycin-resistant breast cancer cell line MDA-MB-231, Taiwanese J. Obstetr. Gynecol., 59, 828-834, \nhttps:\/\/doi.org\/10.1016\/j.tjog.2020.09.008.","journal-title":"Taiwanese J. Obstetr. Gynecol."},{"key":"3004_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s10856-025-06901-7","volume":"36","author":"G. Khodarahmi","year":"2025","unstructured":"Khodarahmi, G., Sabeti, B., and Chekin, F. (2025) Carbon nanotubes\/ordered mesoporous carbon\/chitosan nanocomposite as a promising carrier for everolimus targeted delivery toward lung cancer cells, J. Mater. Sci. Mater. Med., 36, 46, \nhttps:\/\/doi.org\/10.1007\/s10856-025-06901-7.","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"3004_CR44","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-08-2057","volume":"15","author":"H. A. Lane","year":"2009","unstructured":"Lane, H. A., Wood, J. M., McSheehy, P. M., Allegrini, P. R., Boulay, A., Brueggen, J., Littlewood-Evans, A., Maira, S., Martiny-Baron, G., Schnell, C. R., Sini, P., and O\u2019Reilly, T. (2009) mTOR inhibitor RAD001 (everolimus) has antiangiogenic\/vascular properties distinct from a VEGFR tyrosine kinase inhibitor, Clin. Cancer Res., 15, 1612-1622, \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2057.","journal-title":"Clin. Cancer Res."},{"key":"3004_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111428","volume":"40","author":"M. Oro\u0144","year":"2022","unstructured":"Oro\u0144, M., Grochowski, M., Jaiswar, A., Legierska, J., Jastrz\u0119bski, K., Nowak-Niezgoda, M., Ko\u0142os, M., Cybulska, M., Mikula, M., \u017bylicz, A., Mi\u0105czy\u0144ska, M., Zettl, K., Wi\u015bniewski, J.\u00a0R., and Walerych, D. (2022) The molecular network of the proteasome machinery inhibition response is orchestrated by HSP70, revealing vulnerabilities in cancer cells, Cell Rep., 40, 111428, \nhttps:\/\/doi.org\/10.1016\/j.celrep.2022.111428.","journal-title":"Cell Rep."},{"key":"3004_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-6-73","volume":"6","author":"J. Voortman","year":"2007","unstructured":"Voortman, J., Ch\u0119ci\u0144ska, A., and Giaccone, G. (2007) The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells, Mol. Cancer, 6, 73, \nhttps:\/\/doi.org\/10.1186\/1476-4598-6-73.","journal-title":"Mol. Cancer"},{"key":"3004_CR47","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1038\/onc.2009.264","volume":"28","author":"A. Arlt","year":"2009","unstructured":"Arlt, A., Bauer, I., Schafmayer, C., Tepel, J., M\u00fcerk\u00f6ster, S. S., Brosch, M., R\u00f6der, C., Kalthoff, H., Hampe, J., Moyer, M. P., F\u00f6lsch, U. R., and Sch\u00e4fer, H. (2009) Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor\u00a02 (Nrf2), Oncogene, 28, 3983-3996, \nhttps:\/\/doi.org\/10.1038\/onc.2009.264.","journal-title":"Oncogene"},{"key":"3004_CR48","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.bbrc.2021.03.154","volume":"556","author":"C. Liu","year":"2021","unstructured":"Liu, C., Zhou, J., Wang, B., Zheng, Y., Liu, S., Yang, W., Li, D., He, S., and Lin, J. (2021) Bortezomib alleviates myocardial ischemia reperfusion injury via enhancing of Nrf2\/HO-1 signaling pathway, Biochem. Biophys. Res. Commun., 556, 207-214, \nhttps:\/\/doi.org\/10.1016\/j.bbrc.2021.03.154.","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3004_CR49","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.tcb.2012.05.006","volume":"22","author":"S. Kaushik","year":"2012","unstructured":"Kaushik, S., and Cuervo, A.\u00a0M. (2012) Chaperone-mediated autophagy: a unique way to enter the lysosome world, Trends Cell Biol., 22, 407-417, \nhttps:\/\/doi.org\/10.1016\/j.tcb.2012.05.006.","journal-title":"Trends Cell Biol."},{"key":"3004_CR50","doi-asserted-by":"publisher","first-page":"283","DOI":"10.4161\/auto.6.2.11063","volume":"6","author":"J. S. Ju","year":"2010","unstructured":"Ju, J. S., and Weihl, C. C. (2010) p97\/VCP at the intersection of the autophagy and the ubiquitin proteasome system, Autophagy, 6, 283-285, \nhttps:\/\/doi.org\/10.4161\/auto.6.2.11063.","journal-title":"Autophagy"},{"key":"3004_CR51","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/s41556-024-01488-7","volume":"26","author":"S. J. Park","year":"2024","unstructured":"Park, S. J., Son, S. M., Barbosa, A. D., Wrobel, L., Stamatakou, E., Squitieri, F., Balmus, G., and Rubinsztein, D.\u00a0C. (2024) Nuclear proteasomes buffer cytoplasmic proteins during autophagy compromise, Nat. Cell. Biol., 26, 1691-1699, \nhttps:\/\/doi.org\/10.1038\/s41556-024-01488-7.","journal-title":"Nat. Cell. Biol."},{"key":"3004_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/cells10123465","volume":"10","author":"R. Abbas","year":"2021","unstructured":"Abbas, R., and Larisch, S. (2021) Killing by degradation: regulation of apoptosis by the ubiquitin-proteasome-system, Cells, 10, 3465, \nhttps:\/\/doi.org\/10.3390\/cells10123465.","journal-title":"Cells"},{"key":"3004_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-57602-w","volume":"10","author":"A. E. Showalter","year":"2020","unstructured":"Showalter, A. E., Martini, A. C., Nierenberg, D., Hosang, K., Fahmi, N.\u00a0A., Gopalan, P., Khaled, A. S., Zhang, W., and Khaled, A.\u00a0R. (2020) Investigating Chaperonin-Containing TCP-1 subunit 2 as an essential component of the chaperonin complex for tumorigenesis, Sci. Rep., 10, 798, \nhttps:\/\/doi.org\/10.1038\/s41598-020-57602-w.","journal-title":"Sci. Rep."},{"key":"3004_CR54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4161\/auto.6.1.10323","volume":"6","author":"S. Periyasamy-Thandavan","year":"2010","unstructured":"Periyasamy-Thandavan, S., Jackson, W. H., Samaddar, J.\u00a0S., Erickson, B., Barrett, J.\u00a0R., Raney, L., Gopal, E., Ganapathy, V., Hill, W.\u00a0D., Bhalla, K., and Schoenlein, P.\u00a0V. (2010) Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress, and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells, Autophagy, 6, 19-35, \nhttps:\/\/doi.org\/10.4161\/auto.6.1.10323.","journal-title":"Autophagy"},{"key":"3004_CR55","doi-asserted-by":"publisher","DOI":"10.1177\/1533033820957006","volume":"19","author":"D.-W. Wang","year":"2020","unstructured":"Wang, D.-W., Zheng, H.-Z., Cha, N., Zhang, X.-J., Zheng, M., Chen, M.-M., and Tian, L.-X. (2020) Down-regulation of AHNAK2 inhibits cell proliferation, migration and invasion through inactivating the MAPK pathway in lung adenocarcinoma, Technol. Cancer Res. Treat., 19, 1533033820957006, \nhttps:\/\/doi.org\/10.1177\/1533033820957006.","journal-title":"Technol. Cancer Res. Treat."}],"container-title":["Biochemistry (Moscow)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S0006297925603284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1134\/S0006297925603284","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S0006297925603284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:23:26Z","timestamp":1773620606000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1134\/S0006297925603284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3004"],"URL":"https:\/\/doi.org\/10.1134\/s0006297925603284","relation":{},"ISSN":["0006-2979","1608-3040"],"issn-type":[{"value":"0006-2979","type":"print"},{"value":"1608-3040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval and consent to participate.\n                      This work does not contain any studies involving human and animal subjects.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}},{"value":"Conflict of interest.\n                      The authors of this work declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}}]}}